diagnost tool
price close busi august
market leader non-invas blood-
base prenat test enter larg liquid
biopsi cancer organ transplant test market
partnership ahead reiter buy rais pt
deliv anoth solid quarter revenu come ahead our/street
expect larg driven collabor payment partner beij genom
institut bgi expect addit payment bgi anoth major
partnership come opinion may spring thermo fisher use
ion torrent system clear partner world want partner
given highli proprietari massiv multiplex pcr platform technolog
applic across pre-nat test cancer transplant reiter
one top pick reiter buy rate rais pt
rev y/i beat
beat come payment bgi volum y/i beat
panorama nipt horizon carrier screen volum growth
nearli match estim gm beat help
bgi payment y/i volum growth impli us market
leader hold ground quit nice despit nois investor circl suggest rise
competit declin price rev/test increas q/q
acog dialogu folk highest level acog expect posit
new bulletin average-risk nipt unfortun know time
result trim expect benefit acog offset
view higher-than-expect revenu partnership includ bgi
transplant expect launch prospera kidney test expect
draft lcd turn final come month announc launch
proactiv trial patient registri studi kidney largest kind also
launch second prospect multi-cent trial site may quell
stakehold concern tri cut corner
colon cancer medicar coverag submit dossier signatera
colon cancer tam natera estim larger prospera kidney test
given sensit specif data colon cancer stage patient
recurr monitor publish jama oncolog feel good obtain
medicar late
guid rais high end revenue guid
given aforement factor
cancer data mount point see step-funct increas
stock multipl remind investor sit rich bodi data
highlight strong util monitor assay includ breast cancer sensit
specif publish clinic cancer research bladder cancer
sensit specif publish journal clinic oncolog lung cancer
sensit specif assert customized-to-the-pati liquid
biopsi track addit mutat panel thu may detect
relaps anoth panel might miss indic signatera test detect
circul tumor dna ctdna variant allel frequenc vaf cell-fre
dna provid deep depth coverag
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
rais pt pt use multipl revenu estim
discount back two year discount rate dilut share
outstand formerli pt use multipl revenu estim
discount back two year discount rate pro-forma
buy unchang target price august
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price august
diagnost tool
buy unchang target price august
diagnost tool
buy unchang target price august
diagnost tool
